GLP-1 & Incretin Science

A Third Way an Adverse Effect Can Arise

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Beyond off-target toxicity and on-target excess, there is a third category: effects that follow from what a treatment achieves rather than from the treatment itself. Any intervention producing the same physiological change at the same speed would be expected to produce them.

Key facts

Category 1
Off-target toxicity
Category 2
On-target effect, exceeded
Category 3
Consequence of the achievement
Example
Gallstones from rapid weight loss
Example
Retinopathy from rapid HbA1c fall
Test
Would diet or surgery do the same?

Why two categories were not enough

Adverse effects are usually divided into off-target (unrelated to the intended action) and on-target, the intended action carried too far. Neither describes gallstones after rapid weight loss. That is not an unrelated toxicity, and it is not the pharmacology exceeded; it is a consequence of the weight loss itself, which was the goal.

The test that separates the third category

Ask whether a completely different intervention achieving the same result would produce the same effect. Rapid weight loss by dieting or surgery raises gallstone risk, so the answer is yes. Rapid glycaemic improvement by any means is associated with early retinopathy worsening, so again yes. Where the answer is yes, the drug is the vehicle rather than the agent.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why this changes how a signal should be read

An effect in this category cannot be engineered away by improving the molecule, and it does not distinguish between compounds achieving the same result. It also scales with effectiveness. A drug that produces a larger, faster change encounters it more, which makes better drugs look worse on the measure.

The two clear instances on this site

Gallbladder events, where rapid weight reduction is an established gallstone risk factor independent of how the weight was lost. And retinopathy, where the 2018 SUSTAIN analysis frames risk through the reduction in glycated haemoglobin rather than through the compound. Both are documented, and both are routinely reported as drug effects.

Where the categories overlap

They are not always clean. The gallbladder case has a second, drug-specific pathway (suppression of cholecystokinin reducing gallbladder emptying) running alongside the weight loss pathway. So an effect can belong to two categories at once, which is why the question is what proportion rather than which box.

And the fourth possibility, for completeness

That the association belongs to neither the drug nor its achievement but to the condition being treated. This is confounding by indication, as the Danish periconceptional cohort demonstrated when a preterm birth association appeared in the diabetes indication and not in weight management. There are four ways to be wrong about causation, and reporting usually considers one.

Quick reference

CategoryArises fromEngineered away?
Off-targetSomething other than the mechanismIn principle, by selectivity
On-target, exceededThe mechanism itselfNot without weakening the drug
Consequence of achievementThe result, however producedNo, intrinsic to the goal
Confounding by indicationThe underlying conditionNot a drug effect at all

Frequently asked questions

How is this different from an on-target effect?

An on-target effect is the mechanism taken too far. This follows from the result achieved, and would occur with any intervention producing the same change.

What is the test?

Would diet or surgery achieving the same change at the same speed produce it too? If yes, the drug is the vehicle rather than the agent.

Can an effect belong to more than one category?

Yes. Gallbladder events have both a rapid-weight-loss pathway and a drug-specific one through cholecystokinin suppression.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.